References
- . DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281–303
- . Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med. 1998;129(1):36–38
- . Herrine SK, Choudhary C. Severe hepatotoxicity associated with troglitazone. Ann Intern Med. 1999;130(2):163–164
- . Neuschwander-Tetri BA, Isley WL, Oki JC, . Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med. 1998;129(1):38–41
- . Shibuya A, Watanabe M, Fujita Y, . An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care. 1998;21(12):2140–2143
- . Vella A, de Groen PC, Dinneen SF. Fatal hepatotoxicity associated with troglitazone. Ann Intern Med. 1998;129(12):1080
- . Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998;338(13):9166–9917
- . US Food and Drug Administration. Drug Safety Oversight Board. 2008. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm082129.htm. Accessed February 15, 2010
- . Willman D. The rise and fall of the killer drug Rezulin. Los Angeles Times. June 4, 2000
- . Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165(12):1363–1369
- . FDA Consumer Health Information/US Food and Drug Administration. A guide to drug safety terms at FDA. 2008. http://www.fda.gov/down-loads/ForConsumers/ConsumerUpdates/ucm107976.pdf. Accessed February 15, 2010
- . Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140(10):795–801
- . US Food and Drug Administration. Reporting serious problems to FDA. http://www.fda.gov/Safety/MedWatch/HowToReport/default.htm. Accessed January 15, 2010
- . Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–396
- . Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–1259
- . American Society of Health-Systems Pharmacists. ASHP guidelines on adverse drug reaction monitoring and reporting. American Society of Hospital Pharmacy. Am J Health Syst Pharm. 1995;52(4):417–419
- . Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2009;18(6):512–518
- . Segal ES, Valette C, Oster L, . Risk management strategies in the postmarketing period: safety experience with the US and European bosentan surveillance programmes. Drug Saf. 2005;28(11):971–980
- . Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007;30(2):338–344
- . La Grenade L, Lee L, Weaver J, . Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28(10):917–924
- . Aagaard L, Hansen EH. Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs. BMC Clin Pharmacol. 2009;9:4
- . Etwel FA, Rieder MJ, Bend JR, Koren G. A surveillance method for the early identification of idiosyncratic adverse drug reactions. Drug Saf. 2008;31(2):169–180
- . Beghetti M, Hoeper MM, Kiely DG, . Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. Pediatr Res. 2008;64(2):200–204
- . Johann-Liang R, Wyeth J, Chen M, Cope JU. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007. Pharmacoepidemiol Drug Saf. 2009;18(1):24–27
- . US Food and Drug Administration. Tutorial: FDA MedWatch and Patient Safety. http://www.accessdata.fda.gov/videos/MedWatch/tutorial/tutorial_video_flash.htm. Accessed February 15, 2010
- . Olsen AK, Whalen MD. Public perceptions of the pharmaceutical industry and drug safety: implications for the pharmacovigilance professional and the culture of safety. Drug Saf. 2009;32(10):805–810
- . Safer DJ, Zito JM, Gardner JE. Pemoline hepatotoxicity and postmarketing surveillance. J Am Acad Child Adolesc Psychiatry. 2001;40(6):622–629
- . US Food and Drug Administration. Adverse Event Reporting System (AERS). http://www.fda.gov/Drugs/GuidanceComplianceRegulatory-Information/Surveillance/AdverseDrugEffects/default.htm. Accessed January 22, 2010
- . Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. 2001;10(5):407–410
- . US Food and Drug Administration. AERS Reporting by Healthcare Providers and Consumers by Year. http://www.fda.gov/Drugs/Guidance-ComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070456.htm. Accessed February 22, 2010
- . US Food and Drug Administration. CFR–Code of Federal Regulations Title 21, Volume 5. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=310.305. Accessed February 15, 2010
- . US Food and Drug Administration. CFR-Code of Federal Regulations Title 21, Part 314. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314. Accessed February 25, 2010
- . Klepper MJ. The periodic safety update report as a pharmacovigilance tool. Drug Saf. 2004;27(8):569–578
- . US Food and Drug Administration. CFR–Code of Federal Regulations Title 21. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm. Accessed February 23, 2010
- . US Food and Drug Administration. Report to Congress: Reports on postmarketing studies (FDAMA 130). http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm071529.pdf. Accessed February 1, 2010
- . Craigle V. MedWatch: The FDA safety information and adverse event reporting program. J Med Libr Assoc. 2007;95(2):224–225
- . US Food and Drug Administration. HIPAA Compliance for Reporters to FDA MedWatch. http://www.fda.gov/Safety/MedWatch/HowToReport/ucm085589.htm. Accessed February 15, 2010
- . US Food and Drug Administration. Food and Drug Administration Amendments Act (FDAAA) of 2007. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/FDCActChapter-VDrugsandDevices/ucm109090.htm. Accessed June 22, 2010
- . US Food and Drug Administration. FDA adds boxed warning for heart-related risks to anti-diabetes drug Avandia agency says drug to remain on market, while safety assessment continues. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm109026.htm. Accessed February 22, 2010
- . US Food and Drug Administration. Drug safety and availability. Postmarket drug safety information for patients and providers. FDA significantly restricts access to the diabetes drug Avandia. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226975.htm. Accessed October 8, 2010
- . Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7):1017–1025
- . Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. Pharmacotherapy. 2006;26(5):601–608
- . Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ. Reported adverse drug events in infants and children under 2 years of age. Pediatrics. 2002;110(5):e53
- . Mittmann N, Knowles SR, Gomez M, Fish JS, Cartotto R, Shear NH. Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug Saf. 2004;27(7):477–487
- . Smith KM, Jeske CS, Young B, Hatton J. Prevalence and characteristics of adverse drug reactions in neurosurgical intensive care patients. Neurosurgery. 2006;58(3):426–433; discussion 426–433
- . Le J, Nguyen T, Law AV, Hodding J. Adverse drug reactions among children over a 10-year period. Pediatrics. 2006;118(2):555–562
- . US Food and Drug Administration. Reports received and reports entered into AERS by year. http://www.fda.gov/Drugs/GuidanceCompliance-RegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070434.htm. Accessed January 22, 2010
- . Pedros C, Vallano A, Cereza G, . An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Saf. 2009;32(1):77–83
- . Figueiras A, Herdeiro MT, Polonia J, Gestal-Otero JJ. An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. JAMA. 2006;296(9):1086–1093
- . Vallano A, Cereza G, Pedròs C, . Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol. 2005;60(6):653–658
- . Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of underreporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31
- . Belton KJ, Lewis SC, Payne S, Rawlins MD, Wood SM. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol. 1995;39(3):223–226
- . Sweis D, Wong IC. A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain. Drug Saf. 2000;23(2):165–172
- . Nichols V, Thériault-Dubé I, Touzin J, . Risk perception and reasons for noncompliance in pharmacovigilance: a qualitative study conducted in Canada. Drug Saf. 2009;32(7):579–590
- . Irujo M, Beitia G, Bes-Rastrollo M, Figueiras A, Hernàndez-Díaz S, Lasheras B. Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region. Drug Saf. 2007;30(11):1073–1082
- . Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clin Pharmacol. 2009;9:14
- . Herdeiro MT, Figueiras A, Polínia J, Gestal-Otero JJ. Influence of pharmacists' attitudes on adverse drug reaction reporting: a case-control study in Portugal. Drug Saf. 2006;29(4):331–340
- . Herdeiro MT, Figueiras A, Polónia J, Gestal-Otero JJ. Physicians' attitudes and adverse drug reaction reporting: a case-control study in Portugal. Drug Saf. 2005;28(9):825–833
- . Gould DJ, Chudleigh JH, Moralejo D, Drey N. Interventions to improve hand hygiene compliance in patient care. Cochrane Database Syst Rev. 2007(2):CD005186
- . Katz JD. Hand washing and hand disinfection: more than your mother taught you. Anesthesiol Clin North America. 2004;22(3):457–471, vi
- . Trampuz A, Widmer AF. Hand hygiene: a frequently missed lifesaving opportunity during patient care. Mayo Clin Proc. 2004;79(1):109–116
- . Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: Monitoring and patient education–2009. Am J Health Syst Pharm. 2010;67(7):542–558
- . Wald H, Shojania K. Making Health Care Safer: A Critical Analysis of Patient Safety Practices. Evidence Report/Technology Assessment No. 43 (Prepared by the University of California at San Francisco–Stanford), AHRQ Publication No. 01-E058. In: Shojania KG, Duncan BW, McDonald KM, , eds. Rockville, MD: Agency for Healthcare Research and Quality; 2001
- . Institute for Healthcare Improvement. Failure modes and effects analysis (FMEA) tool (IHI Tool). http://www.ihi.org/IHI/Topics/PatientSafety/MedicationSystems/Tools/Failure+Modes+and+Effects+Analysis+%28FMEA%29+Tool+%28IHI+Tool%29.htm. Accessed June 21, 2010
- . Rozich JD, Haraden CR, Resar RK. Adverse drug event trigger tool: a practical methodology for measuring medication related harm. Qual Saf Health Care. 2003;12(3):194–200
- . Cao H, Stetson P, Hripcsak G. Assessing explicit error reporting in the narrative electronic medical record using keyword searching. J Biomed Inform. 2003;36(1–2):99–105
- . Gardner E. Raising a red flag. Programs look for wrong combination of events. Mod Healthc. 2003;33(8):34
- . Ammenwerth E, Schnell-Inderst P, Machan C, Siebert U. The effect of electronic prescribing on medication errors and adverse drug events: a systematic review. J Am Med Inform Assoc. 2008;15(5):585–600
- . Yu F, Salas M, Kim YI, Menachemi N. The relationship between computerized physician order entry and pediatric adverse drug events: a nested matched case-control study. Pharmacoepidemiol Drug Saf. 2009;18(8):751–755
- . Hurdle JF, Weir CR, Roth B, Hoffman J, Nebeker JR. Critical gaps in the world's largest electronic medical record: ad hoc nursing narratives and invisible adverse drug events. AMIA Annu Symp Proc. 2003:309–312
- . Nebeker JR, Hoffman JM, Weir CR, Bennett CL, Hurdle JF. High rates of adverse drug events in a highly computerized hospital. Arch Intern Med. 2005;165(10):1111–1116
- . Ramirez E, Carcas AJ, Borobia AM, . A pharmacovigilance program from laboratory signals for the detection and reporting of serious adverse drug reactions in hospitalized patients. Clin Pharmacol Ther. 2010;87(1):74–86
- . Trifiro G, Pariente A, Coloma PM, . Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18(12):1176–1184
- . Linder J, Haas J, Iyer A, . Secondary use of electronic health record data: spontaneous triggered adverse drug event reporting [published online ahead of print October 11, 2010]. Pharmacoepidemiol Drug Saf.
- . US Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Safety information: Rezulin (troglitazone). Vol 2010; 2000
- . Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch Intern Med. 2007;167(16):1752–1759
- . US Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Safety information: Baycol(cerivastatin sodium tablets) August 2001. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedical-Products/ucm172268.htm. Accessed February 15, 2010
- . Eli Lilly and Company. Lilly announces updates to the Zyprexa and Sym-byax U.S. labels [press release]. http://newsroom.lilly.com/releasedetail.cfm?releaseid=267502. Accessed January 22, 2010
- . Merck. Merck announces voluntary worldwide withdrawal of VIOXX® [press release]. http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf. Accessed June 21, 2010
- . US Food and Drug Administration. Drug Safety and Availability. FDA Drug Safety Communication: FDA Recommends Against the Continued Use of Meridia (sibutramine). http://www.fda.gov/Drugs/DrugSafety/ucm228746.htm. Accessed October 9, 2010
- . US Food and Drug Administration. Drug safety and availability. Post-market drug safety information for patients and providers. Drug safety information for healthcare professionals. Follow-up to the October 2008 updated early communication about an ongoing safety review of tiotropium (marketed as Spiriva HandiHaler). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm197429.htm. Accessed October 9, 2010
- . US Food and Drug Administration. Drug safety and availability. Post-market drug safety information for patients and providers. Drug safety information for healthcare professionals. Information for healthcare professionals: Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm169986.htm. Accessed October 8, 2010
- . AstraZeneca. AstraZeneca decides to withdraw Exanta™ [press release]. http://www.astrazeneca.com/media/latest-press-releases/2006/5217?itemId=3891692. Accessed January 22, 2010